FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386498199> ?p ?o ?g. }

• W4386498199 abstract "Abstract Background Nearly one-third of patients with prostate cancer (PCa) experience biochemical recurrence (BCR) after primary definitive treatment. BCR increases the risk of distant metastasis and mortality in patients with prognostically unfavorable features. These patients are best managed with a tailored treatment strategy incorporating risk stratification using clinicopathological factors, next-generation imaging, and genomic testing. Objective This narrative review examines the utility of risk stratification for the management of patients with BCR in the context of clinical trial data, referencing the latest recommendations by European and US medical societies. Methods PubMed was searched for relevant studies published through May 21 2023 on treatment of patients with BCR after radical prostatectomy (RP) or external beam radiotherapy (EBRT). Results European and US guidelines support the risk-stratified management of BCR. Post-RP, salvage EBRT (with or without androgen deprivation therapy [ADT]) is an accepted treatment option for patients with BCR. Post-EBRT, local salvage therapies (RP, cryotherapy, high-intensity focused ultrasound, stereotactic body radiotherapy, and low-dose-rate and high-dose-rate brachytherapy) have demonstrated comparable relapse-free survival rates but differing adverse event profiles, short and long term. Local salvage therapies should be used for local-only relapses while ADT should be considered for regional or distant relapses. In practice, patients often receive ADT, with varying guidance for intermittent ADT vs. continuous ADT, due to consideration of quality-of-life effects. Conclusions Despite a lack of consensus for BCR treatment among guideline associations and medical societies, risk stratification of patients is essential for personalized treatment approaches, as it allows for an informed selection of therapeutic strategies and estimation of adverse events. In lower-risk disease, observation is recommended while in higher-risk disease, after failed repeat local therapy, ADT and/or clinical trial enrollment may be appropriate. Results from ongoing clinical studies of patients with BCR should provide consensus for management." @default.
• W4386498199 created "2023-09-07" @default.
• W4386498199 creator A5033253417 @default.
• W4386498199 creator A5034131964 @default.
• W4386498199 creator A5036003731 @default.
• W4386498199 creator A5049548593 @default.
• W4386498199 creator A5064878844 @default.
• W4386498199 creator A5088518998 @default.
• W4386498199 date "2023-09-07" @default.
• W4386498199 modified "2023-10-18" @default.
• W4386498199 title "Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification" @default.
• W4386498199 cites W117621210 @default.
• W4386498199 cites W1506304343 @default.
• W4386498199 cites W1521578275 @default.
• W4386498199 cites W1569975580 @default.
• W4386498199 cites W1933794219 @default.
• W4386498199 cites W1977078195 @default.
• W4386498199 cites W1981804745 @default.
• W4386498199 cites W1988298681 @default.
• W4386498199 cites W1998343146 @default.
• W4386498199 cites W2005958584 @default.
• W4386498199 cites W2015607464 @default.
• W4386498199 cites W2022083274 @default.
• W4386498199 cites W2024213847 @default.
• W4386498199 cites W2073988927 @default.
• W4386498199 cites W2093788889 @default.
• W4386498199 cites W2106381426 @default.
• W4386498199 cites W2107270081 @default.
• W4386498199 cites W2107671263 @default.
• W4386498199 cites W2123880024 @default.
• W4386498199 cites W2140905531 @default.
• W4386498199 cites W2150099109 @default.
• W4386498199 cites W2151114651 @default.
• W4386498199 cites W2167854858 @default.
• W4386498199 cites W2167968708 @default.
• W4386498199 cites W2182758908 @default.
• W4386498199 cites W2196246894 @default.
• W4386498199 cites W2346061096 @default.
• W4386498199 cites W2346524736 @default.
• W4386498199 cites W2509573955 @default.
• W4386498199 cites W2550011973 @default.
• W4386498199 cites W2585109238 @default.
• W4386498199 cites W2601335591 @default.
• W4386498199 cites W2610528373 @default.
• W4386498199 cites W2734786464 @default.
• W4386498199 cites W2772104639 @default.
• W4386498199 cites W2783291377 @default.
• W4386498199 cites W2805776890 @default.
• W4386498199 cites W2806842723 @default.
• W4386498199 cites W2810806599 @default.
• W4386498199 cites W2853972740 @default.
• W4386498199 cites W2897445406 @default.
• W4386498199 cites W2913363736 @default.
• W4386498199 cites W2928931548 @default.
• W4386498199 cites W2943710987 @default.
• W4386498199 cites W2944439673 @default.
• W4386498199 cites W2955918565 @default.
• W4386498199 cites W2963649832 @default.
• W4386498199 cites W2964049385 @default.
• W4386498199 cites W2966112499 @default.
• W4386498199 cites W2972275304 @default.
• W4386498199 cites W2972724988 @default.
• W4386498199 cites W2981007717 @default.
• W4386498199 cites W2981066984 @default.
• W4386498199 cites W2983092242 @default.
• W4386498199 cites W2990455595 @default.
• W4386498199 cites W3000715936 @default.
• W4386498199 cites W3008326704 @default.
• W4386498199 cites W3009055724 @default.
• W4386498199 cites W3013251573 @default.
• W4386498199 cites W3013859550 @default.
• W4386498199 cites W3023689102 @default.
• W4386498199 cites W3031020438 @default.
• W4386498199 cites W3038750967 @default.
• W4386498199 cites W3081511520 @default.
• W4386498199 cites W3087977689 @default.
• W4386498199 cites W3088103374 @default.
• W4386498199 cites W3088242837 @default.
• W4386498199 cites W3088359655 @default.
• W4386498199 cites W3091147830 @default.
• W4386498199 cites W3103729469 @default.
• W4386498199 cites W3112578742 @default.
• W4386498199 cites W3113153998 @default.
• W4386498199 cites W3124546863 @default.
• W4386498199 cites W3128646645 @default.
• W4386498199 cites W3128740038 @default.
• W4386498199 cites W3135882965 @default.
• W4386498199 cites W3159170836 @default.
• W4386498199 cites W3159813235 @default.
• W4386498199 cites W3164856190 @default.
• W4386498199 cites W3165110497 @default.
• W4386498199 cites W3198437951 @default.
• W4386498199 cites W3202703903 @default.
• W4386498199 cites W4224078346 @default.
• W4386498199 cites W4281391219 @default.
• W4386498199 cites W4281960705 @default.
• W4386498199 cites W4293168096 @default.
• W4386498199 cites W4319925020 @default.
• W4386498199 cites W4322718353 @default.
• W4386498199 cites W4323569469 @default.

• next